Shady dealings between certain government departments and big business is nothing new, but is the new breakthrough treatment for Alzheimer’s the product of successful research, or old fashioned cronyism? A House investigation found the FDA “collaborated” with Biogen on approval of Alzheimer’s drug Aduhelm. The report revealed “irregularities” in FDA approval process and “collaboration” between Biogen and FDA ahead of advisory committee meeting. Despite none of the 11 panelists voting in favor of approval, the drug was approved. For more information, Lars speaks with Tracy Beanz, who is the Editor of Uncover DC.